Marketing
-
Advocacy group pledges six-figure ad buy to support Trump drug price plan
Patients for Affordable Drugs relaunched a campaign which supports the Trump administration's proposed International Pricing Index for certain drugs.
By Jonathan Gardner • July 17, 2019 -
SponsoredWeathering the privacy storm
How to stay above water in the changing digital marketing landscape.
-
Xarelto falls into the donut hole
A 19% decline from 2018 sales was a dark cloud in an otherwise mostly positive quarterly earnings for Johnson & Johnson.
By Jonathan Gardner • July 16, 2019 -
ICER unconvinced peanut allergy drugs are better than just avoiding the food
The influential cost watchdog group argues that treatments from DBV and Aimmune haven't shown long-term benefits — or, more broadly, quality-of-life improvements.
By Jacob Bell • July 11, 2019 -
Billion-dollar settlement gets Reckitt out of federal opioid probes
Company spinout Indivior, however, is still facing criminal charges related to marketing of Suboxone film, an opioid dependence treatment.
By Jonathan Gardner • July 11, 2019 -
New GSK data raises threat to Gilead's star HIV drug
Dovato, GSK's two-drug HIV treatment, maintained viral suppression about as well as three-drug regimens with a similar makeup to Gilead's Biktarvy.
By Jacob Bell • July 10, 2019 -
UK testing Netflix-style payments to boost antibiotics development
Officials hope the model will overcome some of the obstacles that have stifled the commercial prospects for new antibiotics.
By Jacob Bell • July 09, 2019 -
In win for pharma, Trump TV drug price rule struck down
The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.
By Jonathan Gardner • July 09, 2019 -
BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals
The biotech plans on submitting valrox to U.S. and European regulators in the fourth quarter, which could bring approval decisions by mid-2020.
By Jacob Bell • July 08, 2019 -
Zolgensma set a new drug pricing bar. Insurers show some signs of pushback
One month after approval, a handful of payers have adopted policies taking a more cautious stance than what the FDA set out in the gene therapy's label.
By Ned Pagliarulo • UPDATED: July 5, 2019 at 4:24 p.m. -
BioPharma Dive's 10 biggest stories of the spring
Developments in gene therapy, cancer treatments, drug pricing and dealmaking kept the industry in the headlines.
By Jacob Bell • July 03, 2019 -
Amarin to double sales team again as it boosts Vascepa sales forecast
The drugmaker also plans to start direct-to-consumer advertising in the second quarter of next year, aiming to further grow sales of the fish oil pill.
By Andrew Dunn • July 02, 2019 -
SponsoredA spotlight on patient-provider dialogue
Patient-provider dialogue is a critical part of your brand’s success. Start giving it the attention it deserves.
-
Aiming for price transparency, Civica Rx hits snag with bundled payments
The payment model, often opaque on specific drug costs, affects many of the medicines the hospital-led group is targeting, according to its commercial chief.
By Jacob Bell • June 27, 2019 -
CMS approves Louisiana's 'Netflix model' using Gilead hepatitis C drugs
The subscription model will go into effect Monday, and a similar plan by Washington state is also expected to start next week.
By Rebecca Pifer • June 26, 2019 -
Samsung Bioepis CEO urges patience as US biosimilar market lags
"Market shaping takes time," the head of the Korean drugmaker told BioPharma Dive, as a few experts call to give up on the copycat biologics altogether.
By Ned Pagliarulo • June 26, 2019 -
ColumnPharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Gene therapies and other long-acting treatments are threatening to outdate the drugs Sanofi got from its Bioverativ deal.
By Jacob Bell • June 19, 2019 -
Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says
A Piper Jaffray survey of physicians suggests the new drug won't cannibalize Humira, but instead take market share from Olumiant and Xeljanz.
By Jonathan Gardner • June 14, 2019 -
Allergan reportedly hires Spark Foundry as US advertising agency
The new media agency will come on board as Allergan attempts to mount a turnaround, facing discontent from investors.
By Kristin Jensen • June 12, 2019 -
Influential task force urges payers to cover PrEP for HIV
The recommendation from the U.S. Preventive Services Task Force could expand access to Gilead's Truvada, which has come under scrutiny for its cost.
By Samantha Liss • June 12, 2019 -
SponsoredHow pharma can drive value and embrace change in an evolving marketplace
Pharma sales organizations need to adapt to today's evolving healthcare marketplace.
-
Novo Nordisk goes for broke on semaglutide heart data
The diabetes giant is asking the FDA for permission to market cardiovascular claims before a long-term outcomes study is complete.
By Jonathan Gardner • June 11, 2019 -
Judge, CVS witness clash on merger settlement, July hearing set
Federal Judge Richard Leon told lawyers they might want to cancel their summer vacation plans as he voiced concern about the leverage the merged health giant will wield in the marketplace.
By Dana Elfin • June 06, 2019 -
Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request
Regulators had concerns that data from a key study that has helped Radicava in other markets isn't strong enough to warrant approval in the bloc.
By Jacob Bell • May 31, 2019 -
Seniors' out-of-pocket spending on cancer drugs climbs higher
Despite efforts to limit Medicare Part D beneficiaries' financial exposure to high-cost drugs, price increases have wiped out some of the expected savings.
By Samantha Liss • May 29, 2019
